BC Innovations | Dec 19, 2018
Distillery Therapeutics


INDICATION: Cognitive dysfunction Patient sample and mouse studies suggest inhibiting HMGB1 or reactive oxygen species (ROS) could help treat necrotizing enterocolitis-associated cognitive impairments. In infants with necrotizing enterocolitis, serum levels of HMGB1 and brain levels...
BC Innovations | Nov 26, 2018
Distillery Therapeutics


INDICATION: Epilepsy; seizures Rat studies suggest glycyrrhizin could help treat status epilepticus. In a rat model of lithium-pilocarpine-induced status epilepticus, glycyrrhizin -- which inhibits HMGB1 -- decreased blood-brain barrier (BBB) disruption and hippocampal neuronal damage...
BC Week In Review | Jul 28, 2017
Company News

Feinstein grants Applied Immunotherapeutics rights to HMGB1 candidates

The Feinstein Institute for Medical Research (Manhasset, N.Y.) granted Applied Immunotherapeutics Inc. (Morris, Conn.) exclusive, worldwide rights to three preclinical candidates. Applied Immunotherapeutics gained rights to 2G7 , a mAb against high mobility group box 1...
Items per page:
1 - 3 of 3